HB4462 would substantially revise Oklahoma’s prior authorization rules for health insurance plans. It creates definitions for key terms such as prior authorization, adverse determination, urgent care request, utilization review organization, and health benefit plan, and then imposes strict decision deadlines on insurers and their review contractors. For non-urgent requests, a request is deemed approved if the reviewer does not act within 72 hours, with a limited extension when additional information is requested; urgent requests are deemed approved if not acted on within 24 hours, with similarly short follow-up deadlines after supplemental information is submitted. The bill also requires network providers to submit non-urgent requests at least six days before the scheduled service and to restart the process if they fail to provide complete clinical information within the required time.
The bill further requires prior authorization decisions and appeals to be made by qualified physicians or other licensed health care professionals, not by automated systems alone. It specifically directs utilization review organizations to ensure decision-makers can evaluate and reject artificial intelligence recommendations, and it requires adverse determination notices to include reasons, evidence-based criteria when applicable, appeal instructions, and any additional documentation needed. Appeals must be easy to find on the insurer’s website, and appeal decisions must be issued within 72 hours for non-urgent matters or 24 hours for urgent matters by a different physician than the one who made the original denial.
A major policy change in HB4462 is the creation of a prior-authorization exemption program for certain network providers beginning January 1, 2027. If a provider has treated at least seven patients for a service in 2025 and at least 90% of prior authorization requests for that service were approved, the insurer must exempt that provider from prior authorization for that service in the following year. The exemption can be rescinded for fraud or for anomalous increases in claims, and it can be renewed automatically or after retrospective review. The bill also sets out notice, reconsideration, confidentiality, and final-decision procedures for rescissions and nonrenewals, and it excludes experimental services from the exemption.
In terms of state law impact, the bill would add several new sections to Title 36 of the Oklahoma Statutes and give the Oklahoma Insurance Commissioner rulemaking authority to implement and enforce the act. It would directly affect insurers, health maintenance organizations, nonprofit health care service plans, utilization review organizations, network providers, and enrollees in health benefit plans, while excluding certain limited-benefit products such as Medicare supplement and long-term care coverage. The bill would likely reduce prior authorization delays for some services and providers, while increasing procedural requirements and oversight obligations for insurers and review entities.
No committee transcript or vote record is provided, so there is no recorded debate to gauge legislative sentiment. Based on the bill’s structure, it appears to reflect a pro-provider and pro-patient effort to speed access to care, limit administrative delays, and constrain the use of prior authorization and automated review tools. Potential points of contention are the short turnaround times, the deemed-approved provisions, the mandatory exemption program for high-approval providers, and the limits on insurer discretion in rescinding or denying renewals of exemptions.
HB4462 would amend Oklahoma insurance law by creating new prior authorization standards in Title 36, including mandatory response deadlines, appeal procedures, physician-review requirements, and a new exemption framework for qualifying network providers. It would regulate insurers, utilization review organizations, and health benefit plans, while excluding certain limited-benefit products, and it authorizes the Insurance Commissioner to adopt rules for implementation.
No votes or committee discussion are available, so there is no direct recorded sentiment. The bill’s text suggests a generally favorable posture toward patients and providers by reducing prior authorization barriers and requiring human clinical review, while imposing new compliance duties on insurers and utilization review organizations.
The main likely areas of contention are the strict deemed-approved deadlines, which limit insurer review time; the requirement that physicians or other qualified clinicians, rather than AI-driven systems, make determinations; and the automatic exemption from prior authorization for providers with high approval rates. Insurers may also object to the rescission and renewal limits, the short notice and reconsideration timelines, and the administrative burden of the new notice, appeal, and confidentiality requirements.